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Abstract N-methyl-D-aspartate receptors (NMDARs)
play a pivotal role in the synaptic transmission and synaptic
plasticity thought to underlie learning and memory.
NMDARs activation has been recently implicated in Alz-
heimer’s disease (AD) related to synaptic dysfunction.
Synaptic NMDARs are neuroprotective, whereas overac-
tivation of NMDARs located outside of the synapse cause
loss of mitochondrial membrane potential and cell death.
NMDARs dysfunction in the glutamatergic tripartite
synapse, comprising presynaptic and postsynaptic neurons
and glial cells, is directly involved in AD. This review
discusses that both beta-amyloid (Ab) and tau perturb
synaptic functioning of the tripartite synapse, including
alterations in glutamate release, astrocytic uptake, and
receptor signaling. Particular emphasis is given to the role
of NMDARs as a possible convergence point for Ab and
tau toxicity and possible reversible stages of the AD
through preventive and/or disease-modifying therapeutic
strategies.
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Introduction
Alzheimer’s disease is the most common form of dementia
and the most prevalent neurodegenerative disease charac-
terized by cognitive disorder and memory dysfunction in
the elderly population, affecting almost 40 million people
worldwide [1]. AD progression has been associated with a
gradual damage in function and structure in the hip-
pocampus and neocortex, the vulnerable brain areas
involved in memory and cognition. AD is characterized by
synaptic loss, deposition of Ab plaques, neurofibrillary
tangles (NFTs), and hyperphosphorylated tau. These
changes are associated with NMDARs activation and
oxidative stress which ultimately results in AD pathology.
Besides, Ab is also reported to trigger NMDA-mediated
Ca2? influx, excitotoxicity, and stress-related signaling
pathways in neurons which may exacerbate aging-related
increases in oxidative stress, impaired energy metabolism,
and defective Ca2? homeostasis [2]. The NMDARs are
cationic channels gated by the neurotransmitter glutamate
which play an essential role in excitatory transmission,
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synaptic integration, learning and memory in the central
nervous system (CNS). NMDAR activation, excessive
Ca2? fluxes, and free radical generation are associated with
synaptic dysfunction and tau phosphorylation. Excessive
amounts of glutamate are associated with intense transient
influx of Ca2?, leading to mitochondrial functional
impairments characterized by activation of the permeabil-
ity transition pores in the inner mitochondrial membrane,
cytochrome c release and depletion of ATP, and simulta-
neous formation of ROS [3]. Therefore, it seems that
proper NMDAR and synapse function are necessary for
learning and memory, and improper of NMDAR and
synapse function may participate in the pathogenesis of AD
at the synaptic level.
The NMDAR subtypes associate with neurological
disorders
All glutamate receptor subunits share a common membrane
topology that contain four discrete semiautonomous
domains: the extracellular amino-terminal domain (ATD),
the extracellular ligand-binding domain (LBD), where
glutamate binds to and which created by two regions (S1
and S2) between M3 and M4, the transmembrane domain
(TMD) which contains three transmembrane segments
(M1, M3 and M4) and a re-entrant pore loop (M2), and an
intracellular carboxyl-terminal domain (CTD) which
interacts with multiple cytosolic proteins (Fig. 1). The re-
entrant M2 loop is part of the channel pore and it contains a
critical asparagine residue that determines calcium per-
meability of the channel and mediates the magnesium
blockade [4]. Seven NMDAR subunits have been identi-
fied: one NR1, four NR2 (A, B, C and D), and two NR3 (A,
B) subunits. NR1 occurs as eight distinct splice variants,
likewise, each of the NR2 and NR3 subunits (except
NR2A) has several isoforms. Most native NMDARs are
heterotetramers containing two glycine-binding NR1 and
two glutamate-binding NR2 subunits. The NR1–NR2
dimer is considered to be the basic functional structure in
each receptor. The structure of NDMAR forms a Ca2?-
permeable ion channel. NR3A can also co-assembles with
NR1/NR2 to form a receptor complex. Besides, a portion
of native NMDARs are triheteromers assembled by two
NR1 and two different NR2 subunits [5]. The most
NMDARs contain the obligatory subunit GluN1 plus either
GluN2B or GluN2A or a mixture of the two.
Expression of NMDAR subunits differentially distribute
throughout the brain and change strikingly during devel-
opment. NR1, NR2A and NR2C are mildly expressed in
the temporal region of the cerebral cortex and the hip-
pocampus in the embryonic brain, while in neonatal brain
they express widely throughout the brain. The mRNA of
the NR1 subunit begins to be expressed in the rat brain at
embryonic day 14 and increases gradually until third
postnatal week, since then it decreases to adult levels.
NR2B subunit is mildly expressed in the hippocampus and
the temporal region of the cerebral cortex in fetal brain,
becomes hardly expressed in adults [6]. During postnatal
stage, NR3A protein level is high, decreases from postnatal
week 7 to 21 while NR3B protein expression starts to
increase and NR3A remains low while NR3B remains high
in adult. In humans, NR1 expression is low during gesta-
tion, increases after birth until adolescence and remains
high throughout life. NR3A levels are low in embryonic
day, increases rapidly after birth and declines gradually
into adulthood [7]. The level of NR2B mRNA is signifi-
cantly lower in the neonate than other age groups. While
NR2A mRNA levels remains constant after birth, leading
to an age-related increase in NR2A/2B transcript ratio. It is
believed that the pre- and postnatal expression changes of
NMDAR subunits are important to mediate the synaptic
plasticity lifelong. NMDARs are the primary channel that
mediates Ca2? signals in hippocampal neurons and con-
tribute to the expression of long-term potentiation (LTP)
and long-term depression (LTD) and for synaptic plasticity
[8]. Both NR2A and NR2B subunits are critical for the
induction of LTP and LTD [9]. So, NMDARs mediate key
physiological functions such as learning and memory under
normal conditions.
Several SNPs in the NMDAR subunit genes have been
shown to implicated in the pathophysiology of neurological
disorders, such as AD, schizophrenia, bipolar disorder, and
Fig. 1 Structure and domain organization of NMDA receptors.
Linear representation of the subunit polypeptide chain and schematic
illustration of the subunit topology. NMDARs subunits have a
modular structure composed of two extracellular domains [the ATD
(green) and the LBD (yellow)]; a TMD (cyan) that forms part of the
ion channel pore; and an intracellular CTD. The LBD is defined by
two segments of amino acids termed S1 and S2. The TMD contains
three membrane-spanning helices (M1, M3, and M4) and a membrane
re-entrant loop (M2)
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depression. A missense mutation in the coding regions of
the GRIN2B was found only in the brains of AD patients,
suggesting that close relationship between this mutation of
the postsynaptic NR2B-subunit and alteration of synaptic
structures. Statistical indicate that multiple coding variants
on the risk haplotype containing rs1806201 may play a role
in mediating susceptibility to AD [10]. And also the fre-
quency of Ht2-AG haplotype in GRIN3A gene is higher in
AD patients indicates that GRIN3A variant may represent a
risk in the development of AD [11]. People carrying
insCGTT which is a genetic variation of the NMDAR
NR3B subunit that inserts four bases within the coding
region have a predisposition to schizotypal personality
traits [12]. And the GRIN3A R480G variant showed strong
association with schizophrenia [13]. GRIN2A mutation of
substitution p.N615K is found in a girl with early-onset
epileptic encephalopathy. By analysis of the receptor cur-
rents of NR1-NR2A with the p.N615K mutation, they
found a decrease in Ca2? permeability. So NR2 subunit of
NMDARs affected may disturbance electrophysiological
balance during development which results in variable
neurological phenotypes [14]. In conclusion, NMDARs
SNP variants may affect synaptic transmission and plas-
ticity, results in severe neurological disorders associate
with defective glutamate transmission.
The tripartite glutamate synapse
The term ‘‘tripartite synapse’’ proposed 20 years ago to
describe communication between neurons and astrocytes,
includes a presynaptic terminal, a postsynaptic spine, and
an astrocytic cell (Fig. 2). Within the tripartite synapse are
multiple sites that regulate extracellular glutamate levels
and are sensitive to AD-related pathology. Below, the
normal physiological processes regulating extracellular
glutamate are briefly described, followed by descriptions of
how these targets are deregulated in AD. Glutamate is
packaged into synaptic vesicles by vesicular glutamate
transporters (VGLUTs) presynaptically. Following presy-
naptic neuronal depolarization, calcium channels open,
permitting the influx of calcium and triggering the fusion of
vesicles with the membrane, resulting in the exocytosis of
glutamate into the synapse [15]. Once released the gluta-
mate can activate a variety of ionotropic and metabotropic
receptors on postsynaptic and presynaptic neurons as well
as glial cells. In fact, astrocytes may respond to neuronal
activity through an elevation of internal Ca2? concentra-
tion, which further leads to the release of neurotransmitters
able to cause feedback regulation of neuronal activity and
synaptic efficacy. Perturbations in the glutamatergic tri-
partite synapse may underlie the pathogenic mechanisms of
AD [16]. Glutamate is cleared from the extracellular space
via excitatory amino acid transporters 1/2 (EAAT1/2) by
astrocytes and EAAT2/5 by the presynaptic terminal and
then stored into vesicles [17]. In astrocytes, glutamate is
converted into glutamine (Gln) by glutamine synthetase
and then transported back into the glutamatergic neuron,
where it is hydrolyzed into glutamate by glutaminase.
Additionally, glycine or D-serine serves as a co-agonist to
open the ion channel. If both ligands (glutamate and a co-
agonist) bind while the postsynaptic neuron is in a depo-
larized state, NMDA channels will open, permitting cal-
cium to enter the cells. The increased influx of calcium
transform into chemical signals which in turn, leading to
the establishment of LTP, a process believed to underlie
learning and memory [18]. Overactivation of NMDA
receptors resulting in the elevation of intracellular Ca2?
levels, which initiates a series of events leading to cell
death [19]. In the APPswe-PS1dE9 brain, a mouse model
of AD, NMDAR overactived in an age-dependent manner.
Memantine, a drug that blocks NMDARs, is widely used in
treating AD patients, although its mechanism is still in
debate [20].
Regulation of extracellular concentrations of glutamate
is also essential to neurons. Over-stimulation can let the
synaptic regulation aberrant, leading to alterations in
learning and memory, and more serious, neurodegeneration
[21]. Glutamate transport systems have the potential to
terminate the excitatory signaling, transport glutamate to
extrasynaptic receptors, and protect the neurons from
excitotoxic injury. The majority of glutamate transport in
the CNS, particularly as related to excitatory transmission,
is mediated by the sodium-dependent EAATs. When glu-
tamate release surpasses the capacity of astrocyte clearance
mechanisms, or expression of EAATs decreased, excito-
toxicity can occur. Dysfunction or reduced expression of
GLT-1/EAAT-2 has been documented in both chronic and
acute neurodegenerative disorders [22].
Synaptic and extrasynaptic localization
of NMDARs
N-methyl-D-aspartate receptors subunits differ not only in
temporal pattern of expression, but also in cellular local-
ization. NMDARs have been found on both presynaptic and
postsynaptic locations on neurons. NMDARs existing on
postsynaptic act as detectors for the induction of various
forms of short- and long-term synaptic plasticity. NMDARs
are also located presynaptically where they mediate synaptic
transmission and activity-dependent synaptic plasticity in
developing neural circuits [23]. In interneuron–Purkinje cell
synapse, the NMDA induce an increase in miniature inhi-
bitory postsynaptic currents (mIPSCs) frequency suggesting
the presynaptic NMDARs present on inhibitory axon
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terminals [24]. In pyramidal cells of the developing visual
cortex, presynaptic NMDARs are thought to play a pivotal
role in the regulation of spontaneous neurotransmission and
induction of timing-dependent long-term depression (tLTD)
at pyramidal cell-to-pyramidal cell synapses in layer five.
Synapse-specific presynaptic NMDARs activation could
provide an important mechanism for governing information
processing in neocortical columns during high-frequency
firing [25]. In contrast, presynaptic NMDARs expressing on
interneuron axon terminals appear to act as coincidence
detectors for adjacent glutamatergic and GABAergic activ-
ities, leading to coordinated synaptic modification. More-
over, presynaptic NMDARs may play a role in mediating
spontaneous transmitter release that can dynamically alter
the synaptic efficacy at inhibitory synapses [26].
Extrasynaptic NMDARs are located on dendrites or the
sides of spines and also require high glutamate concen-
trations. In addition, many extrasynaptic NMDARs con-
centrate at points of contact with adjacent processes
including axons, axon terminals, or glia [27]. Many pro-
teins can associate with the NMDARs in these
extrasynaptic sites. Extrasynaptic complexes of PSD-95,
GKAP and shank, and some of these complexes also
contain neuroligin 1. A number of studies suggest that
extrasynaptic NMDARs function may depend on the
receptor type as well as that of associated proteins [28].
Increasing the extrasynaptic glutamate concentration,
including increased stimulation intensities, knockout or
inhibition of the glial glutamate transporter can impair LTP
and this impairment can be prevented by NMDAR antag-
onists, suggesting that extrasynaptic NMDARs can obstruct
activity-dependent plasticity [29]. Ab induces glutamate
release from astrocytes, which in turn activates extrasy-
naptic NMDARs on neurons and subsequent decrease in
miniature excitatory postsynaptic currents (mEPSCs)
which may reflect early synaptic injury [30]. D-serine
degradation inhibits synaptic NMDARs, the magnitude of
LTP expression is attenuated, while glycine degradation
has no effect on LTP, suggesting synaptic NMDARs play a
key role in LTP but not extrasynaptic. On the contrary,
both synaptic and extrasynaptic NMDARs are necessary
for LTD [31].
Fig. 2 The tripartite glutamate
synapse. Neurotransmitter
molecules sequester in vesicles
of the presynaptic neuron,
glutamate is released into the
synaptic cleft. Once released,
glutamate bind to and activate a
variety of ionotropic and
metabotropic receptors on
postsynaptic and presynaptic
neurons as well as glial cells.
The activation of NMDARs
localized in the postsynaptic
membrane leading to Ca2? entry
through the NMDARs and the
propagation of the action
potential. Glutamate can then be
taken up by surrounding
astrocytes through EAAT1/2 or
by the presynaptic terminal
through EAAT2/5, and then
stored into vesicles. The
activation can also be
modulated by glycine released
from neurons and astrocytes or
D-serine released by astrocytes.
Both glycine and D-serine can
also be taken up by the
presynaptic terminal or
astrocytes by their respective
transporters
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Activation of synaptic NMDARs mediates synaptic
plasticity and is thought to be beneficial for neurons,
whereas prolonged activation of NMDARs with subse-
quent overload of Ca2? entry is deleterious [32]. According
to the latest new model, the function of extrasynaptic
NMDARs is related to a variety of locations at different
distances from the nearest synaptic active zones and
arrangements characterized by close association with dif-
ferent kinds of adjacent processes [33]. Synaptic NMDARs
are neuroprotective, whereas stimulation of extrasynaptic
NMDARs cause loss of mitochondrial membrane potential
and cell death. According to this view, it is not the Ca2?
overload is the sole determine neurotoxicity, but rather the
Ca2? influx through NMDARs located outside the synapse
that is particularly harmful to neurons.
Signaling pathways associated with NMDARs
in AD
Many studies have identified key signaling pathways
involved in AD pathogenesis. CREB is the prototypical
signal-regulated transcription factor, plays an essential role
in the maintenance of LTP [34]. Within the hippocampus,
CREB-mediated gene expression are associated with
synaptic plasticity, learning and memory [35]. Phosphory-
lation of CREB at residue ser-133 is particularly important
for its transcriptional activity, which is decreased in AD
[36]. The phosphorylation of CREB can be triggered in
neurons by a variety of signaling processes, including an
increase in intracellular Ca2? via activation of voltage- or
ligand-gated channels such as NMDARs, or activation of
receptor tyrosine kinase by growth factors. Calcium entry
through synaptic NMDARs induced CREB phosphorylation
and BDNF expression, whereas extrasynaptic NMDARs
have the opposite effects, trigger the CREB shut-off path-
way. Ab decreases the phosphorylation of CREB through
inactivation of PKA and thus inhibits LTP generation [37].
Jacob, a caldendrin binding protein in brain, when localized
to the nucleus, attenuates CREB phosphorylation and also
promotes a loss of synaptic contacts. Increased NMDAR
activity was shown to increase the nuclear accumulation of
Jacob [38]. The status of Jacob phosphorylation determines
whether it induces cell death or promotes cell survival and
enhances synaptic plasticity. Phosphorylated Jacob is
translocated to the nucleus after synaptic NMDAR stimu-
lation and is associated with neuroprotection. On the other
hand, nonphosphorylated Jacob is translocated after
extrasynaptic NMDAR stimulation and is associated with
decreased CREB activity, dendritic complexity, and synap-
tic density [39].
Forkhead transcription factor (FoxO3a) is associated
with AD neuropathology and also activated and imported
to nuclear by increased extrasynaptic NMDAR activity
[40]. Synaptic NMDAR activity suppresses FOXO activity
by promoting the Akt-mediated phosphorylation whereas
extrasynaptic NMDAR activity stimulates FOXO nuclear
import and leads to excitotoxic cell death [41]. Extrasy-
naptic NMDARs stimulation leads to activation of calpain,
cleavage of STEP61 to STEP33, accompanied by increase
of p-p38. While synaptic NMDARs activation induces
ubiquitination and degradation of STEP61 which corre-
lated with the phosphorylation of ERK1/2 [42]. The ERK1/
2 pathway, which can induce activation of CREB has been
implicated in NMDAR- mediated neuroprotection.
Synaptic NMDARs activity maintains sustained ERK
activation, whereas activation of all NMDARs by bath
application of NMDA results in ERK activation followed
by inactivation. NMDARs exert a bidirectional role in the
regulation of ERK based on their localization. Synaptic
NMDARs activate ERK whereas the extrasynaptic
NMDARs promote ERK inactivation [43]. Thus, synaptic
and extrasynaptic NMDARs are mutually antagonistic with
regard to ERK signaling.
Ab influence NMDAR involved in AD
The cognitive impairment of AD is closely related to
synaptic plasticity, in which NMDARs plays a critical role.
Activation of NMDARs by Ab accumulation may occur at
early stages of the disease [44]. Ab, like NMDA evoke an
immediately Ca2? rise through activation of GluN2B-
containing NMDARs in cultured cortical neurons [19]. Ab
oligomers is reported to impair NMDARs-dependent LTP
at hippocampal CA1 and dentate gyrus synapses [45]. And
the inhibition of LTP induced by Ab can be prevented by
GluN2B-selective antagonist at low concentrations [46].
Moreover, Ab-induced LTP impairment in AD can be
ameliorated by decreasing extracellular glutamate levels
and inhibition of p38MAPK or calpain, which are selec-
tively activated by extrasynaptic NMDARs [47]. NMDARs
activation raises Ab production by increasing a shift from
a-secretase to b-secretase activity suggesting that even a
mild deregulation of the glutamatergic transmission might
lead to Ab overproduction. In cultured hippocampal neu-
rons, Ab preconditioning reduces surface expression of
NMDAR subunit protein NR1 [48]. Early neuronal dys-
function induced by Ab is mediated by an activation of
NR2B-containing NMDAR in primary neuronal cultures
and hippocampal slices from rat and mouse [49]. More-
over, treatment of rat organotypic slices containing pyra-
midal neurons with Ab oligomers decrease dendritic spine
density and reduce NMDAR-mediated calcium influx into
active spines [50]. GluN1 mRNA levels are significantly
lower in AD, moreover, GluN2A and GluN2B levels are
Neurol Sci (2016) 37:1039–1047 1043
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decreased in susceptible regions of postmortem human AD
brain, such as the hippocampus and the cortex [51]. Since
GluN2A subunits have been implicated in protective
pathways, whereas GluN2B subunits appear to increase
neuronal vulnerability. Activation of GluN2A and decrease
in GluN2B subunit may be an attempt to reduce Ab
induced neuronal dysfunction [52].
Beta-amyloid reduces glutamatergic transmission and
inhibits synaptic plasticity through regulating the number
of NMDARs. When applied to cultured cortical neurons,
Ab enhances endocytosis of NMDARs and decreases
expression of NMDARs [53]. Consistent with the finding
that calcium influx through NMDARs into active spines is
reduced by Ab [50]. Similarly, Ab decreases synaptic
glutamatergic currents in rat hippocampal neurons. Thus,
Ab appears to regulate the synaptic NMDARs, disrupting
the balance between synaptic and extrasynaptic NMDAR
signaling. The expression of glutamate transporters is
reduced significantly both in human tissue from AD
patients [54] and animal models of AD [55].
Tau implicate in excitotoxicity
Like Ab, tau has also been implicated in glutamate exci-
totoxicity and synaptic dysfunction. Tau phosphorylation
results in mislocalization of tau from axons to dendritic
spines and decreased expression of AMPA receptors and
LTP deficits, and subsequently synaptic impairment [56].
The acute overexpression of tau phosphorylation increases
NMDAR transmission and thereby facilitation of LTD.
Phosphorylation of tau can be induced by NMDA receptor
stimulation as well as by incubation with Ab. However, the
acute NMDA receptor-dependent tau phosphorylation is
reversible whereas tau phosphorylation after 5 days of Ab
exposure is not [57]. Fyn is a tyrosine kinase that phos-
phorylates the NR2B receptor subunit, thereby stabilizing
its interaction with PSD95 in dendritic spines. Tau medi-
ates the binding and transport of Fyn to dendritic spines.
Tau reductions cannot transport Fyn to dendritic spines,
prevent the memory deficits and excitability caused by Ab
[58]. Endogenous tau is found at postsynaptic sites where it
binds not only Fyn but also the PSD95-NMDAR complex.
NMDARs activation induces phosphorylation tau at
specific sites, which regulate the interaction of tau with Fyn
and the PSD95-NMDAR complex. Tau phosphorylation
also increases NMDA receptor transmission and facilita-
tion of LTD [57]. Overexpression of human tau in primary
neuronal cultures causes cell death, which is inhibited by
ifenprodil, a GluN2B selective antagonist, suggesting that
tau-induced neurotoxicity by stimulation of extrasynaptic
NMDARs containing GluN2B subunit. Calpain, activated
by Ca2? influx through NMDAR, degrades tau protein into
a toxic N-terminal peptides which leading to cell death
[59]. Memantine treatment preferentially blocks
E-NMDARs, attenuates tau phosphorylation and excito-
toxicity [60]. GluN2A-containing NMDA receptors mod-
ulate tau phosphorylation in rat hippocampal slices.
GluN2A-contained NMDA receptor induces reduction of
tau phosphorylation by a PKC/GSK3 pathway [61].
Although the investigation into the role of tau in glutamate
excitotoxicity is a relatively nascent field, tau play a role in
mediating Ab-induced neuronal death and can induce
synaptic dysfunction independently [62]. Thus, further
elucidation of tau-dependent and tau-independent pathways
is needed, as well as a better understanding of NMDARs in
various pathological effects.
Treatment strategies for AD targeting NMDARs
Several studies reviewed above demonstrate the impor-
tance of NMDARs in AD progression indicating that tar-
geting NMDARs seem to be a promising therapeutic
treatment for AD. Memantine is a NMDA receptor antag-
onist with low-affinity that has been approved by the FDA
for treatment of AD patients. Memantine was shown to
prevent neuronal necrosis, disruption of axonal transport
trafficking, DNA fragmentation and neurite retraction.
Memantine unable to attenuate Ab-induced potentiation of
extracellular glutamate levels but protects neurons by
attenuating tauphosphorylation [60]. Moreover, in 3xTg-
AD mice, memantine treatment ameliorates cognitive
impairment and reduces Ab accumulation and tau phos-
phorylation [63]. In clinical trials, memantine has shown
significant benefits in aspects of cognition such as lan-
guage, memory, praxis, functional communication and in
activities of daily living for AD patients [64]. Neramexane,
a non-competitive NMDAR antagonist, has shown to be
efficient in enhancing long-term memory in adult rats as
memantine, suggesting that this antagonist may have a
potential therapeutic applications [65]. Ifenprodil, a
specific NR2B receptor antagonist, prevents Ab-induced
endoplasmic reticulum stress and hippocampal dysfunction
and microtubule deregulation as well as Ca2? rise [66].
Ifenprodil also prevents Ab-induced inhibition of LTP,
impairment of synaptic transmission and retraction of
synaptic contacts [49]. In acute hippocampal slices, the
selective NR2B antagonists ifenprodil or Ro25-6981 were
also efficient to rescue of LTP inhibition by soluble Ab.
These results suggest that targeting GluN2B subunit of
NMDARs may be another way to prevent AD progression.
Repetitive transcranial magnetic stimulation (rTMS) is a
non-invasive method of brain stimulation which has been
investigated in several neuropsychiatric disorders, such as
AD, Parkinson’s disease and schizophrenia and as a potent
1044 Neurol Sci (2016) 37:1039–1047
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therapeutic tool in depression. rTMS enhance the LTP at
hippocampal CA3-CA1 synapses and increase NR1 and
NR2B expression resulting in improving spatial learning
and memory abilities in the rat model of vascular dementia
[67]. Low-frequency rTMS reverse the decreased NMDAR
levels and deficits in LTP and spatial memory in Ab
induced AD mouse models [68]. rTMS treatment also
improve the cognitive ability and language performance in
AD patients suggesting that rTMS may be a effective
therapeutic technique in the treatment of neurodegenerative
diseases [69].
Conclusions
Glutamatergic dysfunction linked to Ca2? dyshomeostasis
plays a great importance in pathophysiology of AD.
Changes in NMDARs appear to be involved in synaptic
dysfunction in early stages of AD. Recent researches reveal
that in particular the tripartite glutamatergic synapses play
an important role in the pathophysiology of AD, which
provide us a better understanding of this complex and
critical cross-talk mediated by glutamate. These insights
help us to develop new and potentially more effective
compounds as therapeutics for AD. Moreover, differential
regulation of synaptic and extrasynaptic NMDARs seems
to underlie distinct neuronal fates, either inducing cell
survival or cell death. In this regard, selective inhibition of
NMDARs-mediated excitotoxicity alone may help to slow
down the progression of synaptic disruption in AD.
Unfortunately, these therapeutics do not trigger a complete
cure or an improvement in life expectancy when applied in
late stage AD. Thus implementation of earlier therapeutic
strategies targeting NMDARs and the intricate signaling
pathways is needed.
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